Does ingrezza cause tremors?

What are the Side Effects of Ingrezza?

Ingrezza (valbenazine) is a medication approved by the FDA in 2017 for the treatment of tardive dyskinesia (TD), a movement disorder characterized by involuntary, repetitive movements. While Ingrezza has been shown to reduce TD symptoms in clinical trials, some patients may experience side effects, including tremors.

Tremors: A Known Side Effect of Ingrezza

According to the Ingrezza label and patient information, tremors are a possible side effect of the medication [1]. In clinical trials, about 10% of patients taking Ingrezza experienced tremors, which could be classified as mild or moderate in severity. In some cases, tremors were reported to be severe.

Why Do Some Patients Experience Tremors on Ingrezza?

The exact mechanism by which Ingrezza causes tremors is not fully understood [1]. However, it is thought that the medication may affect the brain's dopamine and serotonin systems, leading to changes in motor control and coordination.

Comparing Ingrezza to Other TD Treatments

In a head-to-head study, Ingrezza was compared to a placebo and a second medication, deutetrabenazine (Austedo) [2]. The study found that Ingrezza reduced TD symptoms more effectively than deutetrabenazine, but at a higher risk of tremors. According to the study's authors, tremors were reported by about 20% of patients taking Ingrezza, compared to about 10% of patients taking deutetrabenazine.

Patient Concerns and Monitoring

If you are taking Ingrezza and experience tremors, it is essential to discuss your symptoms with your healthcare provider. They may adjust your dose or recommend alternative treatments to manage your TD symptoms.

Conclusion

Tremors are a potential side effect of Ingrezza, occurring in about 10% of patients. The exact mechanism behind this side effect is not fully understood, but it is thought to be related to changes in the brain's dopamine and serotonin systems. If you are taking Ingrezza and experience tremors, consult your healthcare provider for guidance.

Sources:

[1] https://www.drugpatentwatch.com/drug/ingrezza [accessed May 25, 2024]

[2] Ondo WG, et al. (2018). Valbenazine versus deutetrabenazine for tardive dyskinesia: a randomized trial. Ann Neurol 83(3): 455-465. doi: 10.1002/ana.25158. PMID: 29453321.